Currently, GLP-1 analogs and many other anti-obesity drugs are mostly approved for adolescents aged 12 years and over, limiting pharmaceutical alternatives for youngsters under 12. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.